SCHEMBL1107119

SCHEMBL1107119

CCCSC1c2ccccc2-c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.47
BCHE P06276 1/20 0.47
GPR3 P46089 2/20 0.39
HTR2A P28223 1/20 0.39
MAPT P10636 2/20 0.38
XBP1 P17861 1/20 0.38
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
SOAT1 P35610 1/20 0.36
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8368744 0.73 MAPT (0.47) MAPTXBP1LMNAKDM4ENPC1
SCHEMBL14280080 0.71 MAPT (0.51) MAPTXBP1LMNAKDM4ENPC1
SCHEMBL23686773 0.70 GPR3 (0.46) ACHEBCHEGPR3HTR2AMAPT
SCHEMBL13327250 0.69 GPR3 (0.44) ACHEBCHEGPR3HTR2AMAPT
SCHEMBL9016831 0.68 MAPT (0.56) MAPTXBP1LMNAKDM4ENPC1
SCHEMBL1996543 0.67 HTR2A (0.54) ACHEBCHEGPR3HTR2ACHRM2
SCHEMBL8369184 0.67 MAPT (0.44) ACHEGPR3HTR2AMAPTXBP1
SCHEMBL633764 0.66 HTR2A (0.58) ACHEBCHEGPR3HTR2ACHRM2
SCHEMBL10447563 0.65 ACHE (0.46) ACHEBCHEGPR3HTR2ACHRM2
SCHEMBL313685 0.65 ACHE (0.55) ACHEBCHEGPR3HTR2ACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153667-B2 ATPase inhibitors; Substituted fluorene or benzenerings joined to an alkylene through a sulfone or sulfoxide linkage; without excessive toxicity, irritation, allergic response etc.; sleep dioredrs like excessive sleepiness; Parkinson's disease; Alzheimer's disease; ADD; ADHA; depression, fatigue CEPHALON, INC. (US) 2012-04-10 US disclosed
US-20080070956-A1 Tricyclic aromatic and bis-phenyl sulfinyl derivatives CEPHALON, INC. (US) 2008-03-20 US disclosed
US-7314875-B2 Tricyclic aromatic and bis-phenyl sulfinyl derivatives CEPHALON, INC. (US) 2008-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070956-A1 Tricyclic aromatic and bis-phenyl sulfinyl derivatives PAH, TYR, AHR ACHE 800/4885BCHE 1692/4885GPR3 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.